Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP-001 for ICU respiratory failure due to COVID-19 or ARDS
ACTRN12620000612910Phase 2Completed
- Sponsor
- Cynata Therapeutics
- Start
- May 2021
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cymerus MSCs in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Cynata Therapeutics. Primary endpoints: Trend in P/F ratio trajectory by day 7 and Safety and tolerability. Started May 2021; status: completed.
02
Drugs
Cymerus MSCs
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ACTRN12620000612910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000612910.